07:18 AM EDT, 04/10/2025 (MT Newswires) -- Ideaya Biosciences ( IDYA ) said Thursday it launched a phase 1/2 expansion in a clinical trial of its experimental IDE397 treatment in combination with Gilead Sciences' ( GILD ) Trodelvy in methylthioadenosine phosphorylase, or MTAP-deletion urothelial cancer, based on preliminary safety and clinical efficacy data.

The prevalence of MTAP-deletion is estimated at 26% in the cancer type, the company said. An update on the program is planned later this year.

Ideaya said it is the study sponsor, while Gilead will supply Trodelvy.

Ideaya shares were up 4.4% in recent premarket activity, while Gilead rose 1.4%.